Clinical Trials Browser

Phase 1/2 × pertuzumab × Clear all

NCT04588545 2026-05-26

Radiation Therapy Followed by Intrathecal Trastuzumab/Pertuzumab in HER2+ Breast Leptomeningeal Disease

Phase 1/2 Active not recruiting

Meningeal Neoplasms, Meningeal Carcinomatosis

NCT05593094 2026-05-26

A Phase 1 Trial of ZN-A-1041 Enteric Capsules or Combination in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Solid Tumors

Phase 1/2 Active not recruiting

Brain Neoplasms

NCT06686394 2026-05-22

MK-1022-009

Phase 1/2 Recruiting

Breast Neoplasms

NCT04802759 2026-05-11

A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer

Phase 1/2 Recruiting

Neoplasm Metastasis

NCT05319873 2026-05-11

Ribociclib, Tucatinib, and Trastuzumab for the Treatment of HER2 Positive Breast Cancer

Phase 1/2 Active not recruiting

Anatomic Stage II Breast Cancer AJCC v8

NCT03101748 2026-02-12

Neratinib and Paclitaxel With or Without Pertuzumab and Trastuzumab Before Combination Chemotherapy in Treating Patients With Metastatic or Locally Advanced Breast Cancer

Phase 1/2 Terminated

34 enrolled 15 charts

Breast Neoplasms, Inflammatory Breast Neoplasms

NCT06771622 2026-02-04

Safety and Efficacy of HCB101 in Combination With Multiple Agents in Patients With Advanced Solid Tumors

Phase 1/2 Active not recruiting

Solid Cancer

NCT05150691 2026-01-28

A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors

Phase 1/2 Recruiting

BreastGastrointestinalGynecologicThoracic

Bile Duct Neoplasms, Biliary Tract Neoplasms, Breast Neoplasms, Carcinoma, Carcinoma, Non-Small-Cell Lung, Gastrointestinal Neoplasms, Liver Neoplasms, Neoplasm Metastasis, Neoplasms, Recurrence, Stomach Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma

NCT05256745 2025-12-24

RAGE

Phase 1/2 Recruiting

Cancer Related Cognitive Decline

NCT04538742 2025-12-08

DB-07

Phase 1/2 Active not recruiting

Brain Neoplasms, Breast Neoplasms

NCT04108858 2025-10-01

Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Maintenance Treatment (Trastuzumab and Pertuzumab) After Initial Chemotherapy in a Phase Ib/II Trial for Advanced HER2 Positive Breast Cancer

Phase 1/2 Terminated

2 enrolled 6 charts

Breast Neoplasms

NCT03304080 2025-07-18

Anastrozole, Palbociclib, Trastuzumab and Pertuzumab in HR-positive, HER2-positive Metastatic Breast

Phase 1/2 Active not recruiting

Breast Diseases, Breast Neoplasms

NCT05574881 2024-02-26

Dalpiciclib, Fulvestrant, Trastuzumab and Pertuzumab in HR Positive, HER2 Positive Metastatic Breast Cancer

Phase 1/2 Unknown

Breast Neoplasms

NCT03112590 2023-04-19

Phase I-II Study of Interferon-gamma in Patients With HER-2 Positive Breast Cancer

Phase 1/2 Completed

51 enrolled 13 charts

Breast Neoplasms, Breast Neoplasms, Male

NCT01922921 2023-04-18

Vaccine Therapy With or Without Polysaccharide-K in Patients With Stage IV HER2 Positive Breast Cancer Receiving HER2-Targeted Monoclonal Antibody Therapy

Phase 1/2 Completed

31 enrolled 8 charts

Breast Neoplasms

NCT04750122 2021-04-01

Neoadjuvant Therapy Study Guided by Drug Screening in Vitro for HER2 Positive Early Breast Cancer Patients

Phase 1/2 Recruiting

HER2-positive Early Breast Cancer

NCT02139358 2021-02-04

Phase I/IIa Trial of Gemcitabine Plus Trastuzumab and Pertuzumab in Previously Treated Metastatic HER2+ Breast Cancer

Phase 1/2 Completed

15 enrolled 12 charts

Breast Neoplasms, Neoplasm Metastasis

NCT02336984 2021-01-11

A Phase I/II Trial of HER-2/Neu Pulsed DC1 Vaccine Combined With Trastuzumab for Patients With DCIS

Phase 1/2 Withdrawn

Breast Neoplasms, Carcinoma, Intraductal, Noninfiltrating

NCT02120911 2020-07-01

TRAP

Phase 1/2 Completed

Gastrointestinal

Esophageal Neoplasms

NCT02379585 2018-04-24

STEFNE

Phase 1/2 Terminated

8 enrolled 1 chart

HER2-positive Breast Cancer

NCT02345772 2018-02-20

Neohttp

Phase 1/2 Terminated

4 enrolled 1 chart

HER2-positive Breast Cancer

NCT00934856 2017-04-06

A Study of Trastuzumab Emtansine (T-DM1) in Combination With Docetaxel, and Potentially Pertuzumab, in Participants With Advanced Breast Cancer

Phase 1/2 Completed

98 enrolled 40 charts

Breast Neoplasms

NCT00951665 2016-06-24

A Study of Trastuzumab Emtansine, Paclitaxel, and Pertuzumab in Patients With HER2-Positive, Locally Advanced or Metastatic Breast Cancer

Phase 1/2 Completed

107 enrolled 31 charts

Breast Neoplasms

NCT00551421 2015-03-31

Pertuzumab and Cetuximab in Treating Patients With Previously Treated Locally Advanced or Metastatic Colorectal Cancer

Phase 1/2 Completed

17 enrolled 7 charts

Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms

NCT00875979 2013-12-24

A Study of Trastuzumab Emtansine (Trastuzumab-MCC-DM1, T-DM1) in Combination With Pertuzumab Administered to Patients With Human Epidermal Growth Factor Receptor-2 (HER2)-Positive Locally Advanced or Metastatic Breast Cancer Who Have Previously Received Trastuzumab

Phase 1/2 Completed

67 enrolled 9 charts

Breast Neoplasms